Expectations for Pfizer have been low, says Mizuho's Jared Holz on weight-loss pill setback

Expectations for Pfizer have been low, says Mizuho's Jared Holz on weight-loss pill setbackПодробнее

Amgen has 'a lot to prove' in the weight-loss drug category, says Mizuho's Jared HolzПодробнее

Weight loss drug market is just beginning to take off, says Mizuho's Jared HolzПодробнее

Mizuho's Jared Holz reacts to JPMorgan's huge obesity drug callПодробнее

Drugs for obesity are a massive market, says Mizuho's Jared HolzПодробнее

Obesity drug enthusiasm can continue in 2024: Mizuho's Jared HolzПодробнее

Blocking the Horizon-Amgen deal will be worse for pharma than for biotech, says Mizuho's Jared HolzПодробнее

Pfizer to Deliver U.S. Vaccine Doses Two Months Early, CEO SaysПодробнее

Mizuho's Holz on weight loss drugs: Lilly and Novo Nordisk are in excellent shape fundamentallyПодробнее

Election noise may make pharmaceutical stocks 'untenable' for investors, says Mizuho's Jared HolzПодробнее

Biogen has been an 'uninvestable' stock for awhile, says Mizuho's Jared HolzПодробнее

BMO's Evan Seigerman says Pfizer's dip is a setback and not catastrophicПодробнее

Should you buy Pfizer stock? (December 2023)Подробнее

Current job market favors skills over degrees, says Recruiter.com's Evan SohnПодробнее

Pfizer Stock is at a 52 Week Low! | Pfizer (PFE) Stock Analysis! |Подробнее

Nvidia is a generational story for now, says Fundstrat's Tom LeeПодробнее

Eli Lilly and Novo Nordisk will remain leaders in the weight-loss drug market: Mizuho's Jared HolzПодробнее

Regulators target AI in Big Tech and financialsПодробнее

It doesn't seem like there's too much momentum for healthcare stocks, says Mizuho's Jared HolzПодробнее

Campbell Soup CEO talks 'positive' acquisition of Sovos BrandsПодробнее